Search Results - "Buse, Dawn C."

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study.

Authors: Katsarava, Zaza Buse, Dawn C Leroux, Elizabeth et al.

Source: Cephalalgia. Aug2024, Vol. 44 Issue 8, p1-9. 9p.

Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

Authors: Buse, Dawn C. Lipton, Richard B. Urman, Robert et al.

Source: Neurology & Therapy. Feb2026, Vol. 15 Issue 1, p401-420. 20p.

Use of mediation modeling to examine the relationships among treatment with rimegepant, headache pain severity, and functional disability in patients with migraine.

Authors: Abraham, Lucy Bushmakin, Andrew G. Buse, Dawn C. et al.

Source: Cephalalgia Reports. 3/24/2026, Vol. 9, p1-10. 10p.

Unmet treatment needs in migraine: Results of the OVERCOME (US) study.

Authors: Hutchinson, Susan Johnston, Elizabeth Nicholson, Robert A. et al.

Source: Headache: The Journal of Head & Face Pain. Apr2026, Vol. 66 Issue 4, p896-908.

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study.

Authors: Buse, Dawn C. Videnieks, Lindsay A. Charles, Karissa et al.

Source: Headache: The Journal of Head & Face Pain. Apr2026, Vol. 66 Issue 4, p859-873.

Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies.

Authors: Buse, Dawn C. Versijpt, Jan Diener, Hans-Christoph

Source: Neurology & Therapy. Aug2025, Vol. 14 Issue 4, p1185-1196. 12p.

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial.

Authors: Schuster, Nathaniel M. Wallace, Mark S. Marcotte, Thomas D. et al.

Source: Headache: The Journal of Head & Face Pain. Feb2026, Vol. 66 Issue 2, p365-376.

Author index.

Source: Cephalalgia. Jun2007, Vol. 27 Issue 6, p760-771. 12p.

Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care.

Authors: Adams, Aubrey Manack Buse, Dawn C. Leroux, Elizabeth et al.

Source: Cephalalgia. Jun2023, Vol. 43 Issue 6, p1-13. 13p.

Headache/migraine-related stigma, quality of life, disability, and most bothersome symptom in adults with current versus previous high-frequency headache/migraine and medication overuse: results of the Migraine Report Card survey.

Authors: Buse, Dawn C. Cady, Roger Starling, Amaal J. et al.

Source: BMC Neurology. 7/4/2024, Vol. 24 Issue 1, p1-17. 17p.

Author index.

Source: Quality of Life Research. Oct2016 Supplement, Vol. 25, p197-214. 18p.

Subjects: Aaronson, Neil K., Abbasi, Behnood, Abernethy, Amy

Response to: Disagreement with Categorization of Clinical Trials included in Treadwell et al. Systematic Review and Meta‐Analysis.

Authors: Treadwell, Jonathan R. Ivlev, Ilya Rouse, Benjamin et al.

Source: Headache: The Journal of Head & Face Pain. Oct2025, Vol. 65 Issue 9, p1505-1506. 2p.

Subjects: Migraine prevention, Mindfulness, Treatment effectiveness, Magnetic resonance imaging, Telemedicine, Attention, Psychological stress, Health education, Migraine, Behavior therapy, Children, Adults

Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.

Authors: Buse, Dawn C. Krasenbaum, Lynda J. Seminerio, Michael J. et al.

Source: Pain & Therapy. Jun2024, Vol. 13 Issue 3, p511-532. 22p.

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study.

Authors: Buse, Dawn C. Muenzel, E. Jolanda Zagar, Anthony J. et al.

Source: Headache: The Journal of Head & Face Pain. Apr2025, Vol. 65 Issue 4, p589-607.

Behavioral interventions for migraine prevention: A systematic review and meta‐analysis.

Authors: Treadwell, Jonathan R. Tsou, Amy Y. Rouse, Benjamin et al.

Source: Headache: The Journal of Head & Face Pain. Apr2025, Vol. 65 Issue 4, p668-694.

Global perspectives on the burden of episodic and chronic migraine.

Authors: Buse, Dawn C Lipton, Richard B

Source: Cephalalgia. Aug2013, Vol. 33 Issue 11, p885-890. 6p.

Development of the Migraine‐Related Stigma (MiRS) Questionnaire: Results of the OVERCOME (US) Study.

Authors: Seng, Elizabeth K. Muenzel, E. Jolanda Shapiro, Robert E. et al.

Source: Headache: The Journal of Head & Face Pain. Feb2025, Vol. 65 Issue 2, p269-279.

Symptoms across the phases of the migraine cycle from the patient's perspective: Results of the MiCOAS qualitative study.

Authors: McGinley, James S. Mangrum, Rikki Gerstein, Maya T. et al.

Source: Headache: The Journal of Head & Face Pain. Feb2025, Vol. 65 Issue 2, p303-314.

The prevalence of hypnic headache in Iceland.

Authors: Eliasson, Jon H Scher, Ann I Buse, Dawn C et al.

Source: Cephalalgia. Jul2020, Vol. 40 Issue 8, p863-865. 3p.

Stigmatizing attitudes toward people with migraine by people without active migraine: results of the OVERCOME (US) study.

Authors: Shapiro, Robert E. Viktrup, Lars Muenzel, Eva Jolanda et al.

Source: BMC Neurology. 3/12/2025, Vol. 25 Issue 1, p1-12. 12p.